What it is
Vitamin B12 is a vitamin your body cannot make and has to get from food — mainly meat, fish, eggs, and dairy. It is essential, meaning without enough of it things go wrong.
Methylcobalamin is the form used here. B12 comes in several chemical forms; methylcobalamin is one of the two that the body can use directly, without having to convert it first.
It matters most in two places. It is essential for myelin, the insulating coating around your nerves — nerves without proper myelin do not carry signals well, which is why B12 deficiency shows up as numbness, tingling, and brain fog. And it is central to methylation, a chemical process the body runs constantly to build, switch on, and clear out an enormous range of molecules.
It comes as a ready-mixed solution. Nothing is reconstituted. You draw a dose and inject it into a muscle, an intramuscular injection.
B12 is also an ingredient in Lipo Shredder, one of the lipotropic injections on this site.
Methylcobalamin — the methylated, directly bioactive cobalamin form, requiring no conversion step, unlike cyanocobalamin.
Supplied ready-mixed for intramuscular administration; no reconstitution.
The two key functional domains are myelin integrity — hence the deficiency presentation of peripheral neuropathy, cognitive fog, and paraesthesia — and methylation, where cobalamin is the cofactor for methionine synthase in the remethylation of homocysteine.
Cobalamin is also a declared constituent of the Lipo Shredder lipotropic on this site, at an undeclared quantity.
Note on the risk picture: there is a well-defined deficiency-signs list and a set of excess-accumulation signs but only a single formal contraindication, so the documentation is stronger on repletion than on risk.
What it does
The headline benefit is energy — more of it, and at the level of the cell rather than just subjectively.
It boosts metabolism, and helps break down carbohydrates and proteins.
It reduces brain fog, because of the myelin coating it supports on your nerves, which improves brain function and mental clarity.
It helps the liver process chemical waste, supports hormone production, and helps regulate blood sugar.
It helps mood and focus, and combats stress.
It supports methylation and detox pathways — the chemical processes the body uses to build and clear molecules.
And it helps with the numbness and tingling that people with neuropathy — nerve damage — experience.
It also helps to know what running low looks like, which is the clearest statement of what B12 is doing when it is present: fatigue, shortness of breath, dizziness on standing up, insomnia, loss of concentration and memory, depression, muscle weakness, irritability, a raised heart rate, a weakened immune system, burning in the mouth and tongue, sudden unexpected blurred vision, and balance problems.
Claimed effects: increased energy; metabolic support including carbohydrate and protein breakdown; reduced cognitive fog via myelin support with improved brain function and mental clarity; cellular energy support; hepatic processing of chemical waste; support of hormone production; blood sugar regulation; mood and focus support; stress mitigation; support of methylation and detoxification pathways; and symptomatic benefit for numbness and paraesthesia in neuropathy patients.
The deficiency presentation is, in effect, the mechanism read backwards: fatigue, dyspnoea, orthostatic hypotension, insomnia, impaired concentration and memory, depression, muscle weakness, irritability, tachycardia, decreased immune function, glossitis and oral burning, sudden blurred vision, and balance disturbance. The haematological and neurological halves of that list correspond to the two classical deficiency syndromes — megaloblastic anaemia and subacute combined degeneration.
These claims are not differentiated between repletion in deficiency and supplementation in sufficiency; they are stated for both populations without qualification.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- More energy — the headline benefit.Limited human data
- Boosts metabolism, and assists in breaking down carbohydrates and proteins.Anecdotal
- Less brain fog, because B12 is essential to the myelin coating on your nerves, which improves brain function and mental clarity.Limited human data
- Boosts energy at the level of the cell.Anecdotal
- Helps the liver process chemical waste.Anecdotal
- Supports hormone production.Anecdotal
- Regulates blood sugar.Anecdotal
- Breaks down carbohydrates.Anecdotal
- Helps mood and focus.Limited human data
- Combats stress.Anecdotal
- Helps methylation and detox pathways.Anecdotal
- Helps with the numbness and tingling that people with nerve damage experience.Human trials
- Increased energy — the lead claim.Limited human data
- Metabolic support, including carbohydrate and protein catabolism.Anecdotal
- Reduced cognitive fog through myelin support, with improved brain function and mental clarity.Limited human data
- Cellular energy support.Anecdotal
- Hepatic processing of chemical waste.Anecdotal
- Support of hormone production.Anecdotal
- Blood sugar regulation.Anecdotal
- Carbohydrate breakdown.Anecdotal
- Mood and focus support.Limited human data
- Stress mitigation.Anecdotal
- Support of methylation and detoxification pathways.Anecdotal
- Symptomatic benefit for numbness and paraesthesia in neuropathy.Human trials
- Benefits are asserted uniformly, without distinguishing correction of deficiency from supplementation in a replete individual. The deficiency-signs list is the better guide to who has most to gain.Anecdotal
Reconstitution and dosing
The vial comes ready-mixed. Nothing is reconstituted.
Inject into a muscle — that is preferred. Under the skin is acceptable but less effective.
Take it in the morning. You may take it with or without food.
There are two protocols, and both have the same shape: a loading cycle of weekly injections, then a maintenance dose that continues indefinitely with no set end point.
Standard protocol. Weeks 1 to 4: 5,000 micrograms (50 units) once a week. Then maintenance: 2,500 to 5,000 micrograms (25 to 50 units) once a month, indefinitely.
Maximum protocol. Weeks 1 to 10: 5,000 micrograms (50 units) once a week. Then maintenance: 5,000 micrograms (50 units) one to two times a month, indefinitely.
So the difference between them is how long the weekly loading phase runs — four weeks or ten — and how much you take afterwards.
About the numbers in the table. 50 units is paired with 5,000 micrograms, which means 1 unit is 100 micrograms — 10 milligrams in every millilitre. No vial size is assumed. The table uses a placeholder vial of 100 mg in 10 mL, chosen because it reproduces that strength exactly; every unit figure below matches it. The vial size is a placeholder; the strength is 10 mg/mL.
One thing to be aware of before starting an open-ended course: excess B12 has recognisable signs (see side effects), but there is no established advice about testing your levels, and no point at which to stop.
Ready-mixed solution; no reconstitution.
Intramuscular administration preferred; subcutaneous acceptable but less effective. Morning dosing. With or without food.
Two protocols, both structured as a weekly loading phase followed by open-ended maintenance.
Standard protocol: weeks 1–4 at 5,000 mcg (50 units) 1×/week, then maintenance at 2,500–5,000 mcg (25–50 units) 1×/month indefinitely, with no defined maintenance period.
Maximum protocol: weeks 1–10 at 5,000 mcg (50 units) 1×/week, then maintenance at 5,000 mcg (50 units) 1–2×/month indefinitely.
The protocols differ only in loading duration (4 versus 10 weeks) and maintenance intensity. Cumulative loading exposure is 20 mg versus 50 mg of methylcobalamin.
Concentration basis and disclosure. The dosing pairs 50 units with 5,000 mcg and 25 units with 2,500 mcg, giving 100 mcg per insulin unit — 10 mg/mL. No vial volume or mass is fixed. The protocols below carry a derived placeholder of 100 mg in 10 mL, chosen to reproduce 10 mg/mL exactly. Every computed draw matches the unit figures with zero divergence. The concentration is the stated basis; the vial size is not.
A note on that concentration: 10 mg/mL is high for a cobalamin preparation — common clinical presentations run 1 mg/mL, at which 5,000 mcg would be 5 mL rather than 0.5 mL. The unit and microgram figures are internally consistent at 10 mg/mL, so that is what is used, but check the concentration printed on the vial you actually have before drawing 50 units.
The structural gap is monitoring. Both protocols run indefinitely, an excess-accumulation syndrome is recognised, and no assay, endpoint, or review interval is specified anywhere.
Standard protocol — 4-week cycle, then indefinite maintenance
Ready-mixed solution — nothing to reconstitute. 50 units = 5,000 mcg, i.e. 100 mcg per insulin unit (10 mg/mL); no vial size is assumed, and the 100 mg in 10 mL here is a placeholder reproducing that strength exactly. Check the concentration printed on your own vial, since 1 mg/mL is the more common commercial presentation.
10 mg/mL · 100 mcg per unit
Cycle: 4 weeks of weekly dosing, then maintenance monthly with no set end point · Frequency: Intramuscular preferred, subcutaneous acceptable but less effective; morning; with or without food
| When | Dose | Draw | How often |
|---|---|---|---|
| Weeks 1–4 (50 units) | 5 mg | 50 units | 1×/week |
| Maintenance — low end, 2,500 mcg (25 units) | 2.5 mg | 25 units | 1×/month, indefinitely |
| Maintenance — top of range, 5,000 mcg (50 units) | 5 mg | 50 units | 1×/month, indefinitely |
Maximum protocol — 10-week cycle, then indefinite maintenance
Ready-mixed solution; no reconstitution. The 100 mg in 10 mL is a placeholder reproducing 100 mcg per insulin unit (10 mg/mL); no vial size is assumed.
10 mg/mL · 100 mcg per unit
Cycle: 10 weeks of weekly dosing, then maintenance one to two times monthly with no set end point · Frequency: Intramuscular preferred, subcutaneous acceptable but less effective; morning; with or without food
| When | Dose | Draw | How often |
|---|---|---|---|
| Weeks 1–10 (50 units) | 5 mg | 50 units | 1×/week |
| Maintenance (50 units) | 5 mg | 50 units | 1–2×/month, indefinitely |
100 mg in 10 mL is 10 mg/mL, or 100 mcg per unit. Draw 50 units (0.5 mL) for 5000 mcg.
Who should avoid it
- Anyone with chronic kidney problems. Supplemental B12 should not be used in that case, and it is the only established contraindication.
- No drug interactions have been documented for B12.
- No information is available on pregnancy and breastfeeding, in either direction.
- No caution has been established about metformin or about acid-reducing medication, both of which are well-established causes of low B12 — and knowing you are on one of them would change how you read the deficiency list above. The stacking section below mentions that GLP-1 agonists can deplete B12, so drug-induced depletion is a real consideration.
- There is no established advice on testing B12 levels before or during use, and the maintenance protocols run indefinitely with no stopping point. Given that excess B12 has recognised signs, the absence of any monitoring guidance is the notable gap.
- Chronic renal disease — the only established contraindication: supplemental B12 is not to be used.
- No drug interactions have been documented.
- Pregnancy and lactation are unaddressed.
- Metformin and proton pump inhibitors — the two best-characterised iatrogenic causes of cobalamin depletion — have no documented guidance, despite GLP-1-associated depletion being acknowledged in the stacking section. Drug-induced depletion is raised as a reason to supplement but never as a diagnostic consideration.
- No baseline or follow-up assay is specified, and both maintenance protocols run indefinitely with no defined endpoint. This sits directly against the excess-accumulation signs listed under side effects.
- There is no established guidance on folate. Cobalamin repletion in the presence of folate deficiency, or vice versa, is the classical monitoring concern in this area, and methylfolate is suggested as a stack partner below without that caution being addressed.
Side effects
- Side effects are described as symptoms of too much B building up in the system, rather than as effects of a normal dose.
- Headaches.
- Nausea.
- Vomiting.
- Diarrhoea.
- Skin problems — itching, rashes, acne.
- More serious signs of excess: heart problems.
- More serious signs of excess: blood clots.
- More serious signs of excess: neurological symptoms including tingling, numbness, confusion, and disorientation.
- The serious excess symptoms — tingling, numbness, confusion — are the same symptoms listed as signs of B12 deficiency. Without testing there is no way to tell which one you are looking at, and no testing advice has been established.
- No injection site reaction is documented, which is unusual for something given into muscle.
- Adverse effects are framed as symptoms of excess B accumulation rather than as dose-related effects.
- Headache.
- Nausea.
- Vomiting.
- Diarrhoea.
- Cutaneous effects: pruritus, rash, acne.
- More serious excess presentation: cardiac events.
- More serious excess presentation: thrombosis.
- More serious excess presentation: neurological symptoms including paraesthesia, numbness, confusion, disorientation.
- The severe excess presentation and the deficiency presentation overlap almost exactly on the neurological symptoms — paraesthesia, numbness, and cognitive disturbance appear in both. With no assay guidance available, the two are clinically indistinguishable on the information given.
- No injection site reaction is documented despite intramuscular administration.
- The excess warning refers to "excess buildup of B" rather than B12 specifically, which reads as generic B-complex language. The distinction matters, since cobalamin and pyridoxine have very different toxicity profiles, and pyridoxine excess is the one that classically presents as peripheral neuropathy.
User reports
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
Lipo-C complements B12 for fat metabolism, liver detox, and increased energy. MIC+C is the other name for it — the letters stand for methionine, inositol, and choline, the three nutrients at the core of that formula, with the C for vitamin C. The Lipo-C entry makes the same suggestion in reverse.
A reciprocal pairing. MIC+C denotes the classic lipotropic trio — methionine, inositol, choline — with ascorbate; the Lipo-C formulation on this site declares methionine, choline chloride, L-carnitine, and dexpanthenol rather than inositol, so the trade name and the declared formula do not fully align. Either way it supplies the transmethylation and fat-transport arms, and B12 supplies the cobalamin cofactor those depend on. Note that Lipo Shredder already contains B12 and Lipo-C does not.
This is described as synergistic cellular energy support and mitochondrial optimisation — both work on how cells produce energy, by different routes.
Suggested for synergistic cellular energy support and mitochondrial optimisation. Different nodes of the same energy metabolism — cobalamin as a methylation and one-carbon cofactor, NAD+ as a redox coenzyme.
B12 is suggested alongside the GLP-1 weight-loss drugs, because those drugs can deplete B12.
Suggested to counter GLP-1-receptor-agonist-associated B12 depletion. This is the only documented acknowledgement of drug-induced cobalamin depletion, and it appears as a stacking rationale rather than in any interaction list.
Suggested for supporting antioxidant regeneration and detox pathways alongside B12.
Suggested for antioxidant regeneration and detoxification support. Both sit on the transsulfuration and one-carbon pathways, which is the mechanistic basis for the pairing.
- Folate (methylfolate)
Paired with B12 for improved methylation and for regulating homocysteine, a substance in the blood that both vitamins help clear.
Suggested for improved methylation and homocysteine regulation. This pairing does not address the classical caution that folate repletion can mask the haematological signs of cobalamin deficiency while neurological damage progresses — which is less relevant when both are given together, but is the reason the pair is usually discussed as a pair.
Dosing figures have been reviewed and units are recomputed from the stated protocol.